Zhongzhi Pharmaceutical Holdings Limited (3737.HK)

HKD 0.91

(0.0%)

Market Cap (In HKD)

769.22 Million

Revenue (In HKD)

2.04 Billion

Net Income (In HKD)

162.77 Million

Avg. Volume

195.67 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.82-1.48
PE
-
EPS
-
Beta Value
0.525
ISIN
KYG989611085
CUSIP
G98961108
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Zhi Tian Lai
Employee Count
-
Website
https://www.zeus.cn
Ipo Date
2015-07-13
Details
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.